Cancers, Vol. 16, Pages 1379: Advancing GCT Management: A Review of miR-371a-3p and other miRNAs in Comparison to Traditional Serum Tumor Markers

Cancers, Vol. 16, Pages 1379: Advancing GCT Management: A Review of miR-371a-3p and other miRNAs in Comparison to Traditional Serum Tumor Markers

Cancers doi: 10.3390/cancers16071379

Authors: Crystal L. Seales Dhruv Puri Nuphat Yodkhunnatham Kshitij Pandit Kit Yuen Sarah Murray Jane Smitham John T. Lafin Aditya Bagrodia

MicroRNAs, short non-protein coding RNAs, are overexpressed in GCTs. Circulating levels of germ cell tumor (GCT)-associated miRNAs, such as miR-371a-3p, can be utilized as efficient and cost-effective alternatives in diagnosing and managing patients presenting with GCTs. This quality of miRNAs has demonstrated favorable performance characteristics as a reliable blood-based biomarker with high diagnostic accuracy compared to current serum tumor markers (STMs), including α-fetoprotein (AFP), beta human chorionic gonadotropin (β-hCG), and lactate dehydrogenase (LDH). The conventional STMs exhibit limited specificity and sensitivity. Potential clinical implications of miRNAs include impact on de-escalating or intensifying treatment, detecting recurrence at earlier stages, and lessening the necessity of cross-sectional imaging or invasive tissue biopsy for non-teratomatous GCTs. Here, we also highlight the outstanding issues that must be addressed prior to clinical implementation. Standards for measuring circulating miRNAs and determining ideal cutoff values are essential for integration into current clinical guidelines.